

In-line results; robust FY25 guidance

Information Technology ▶ Result Update ▶ May 3, 2024

TARGET PRICE (Rs): 220

FSOL's Q4 results were broadly in line with our estimates. Revenue growth of 4.7% QoQ was slightly higher than our estimate of 3.9% QoQ, while EBITM of 11% was in line. Both, revenue growth and logo additions have been broad-based across geographies and verticals. It guided 10-13% CC YoY growth for FY25, considering strong deal intake in FY24 (highest-ever ACV win) and robust pipeline (25% growth in Q4). FY25 guidance factor-in the impact of QBSS acquisition and residual offshore shift in top clients, implying a CQGR of 2-3%. It plans to frontload investments in sales (expanded team size by ~33% in 6M), capabilities (leadership and solutions), and brand positioning. Management aims to deliver USD1bn organic revenue run rate by FY26-end (implied CQGR of ~2.8%), and expand EBITM by 50-75bps each year over the medium term after the investment phase. We cut FY25-26E EPS by 2-4% to factor-in the Q4 performance, slightly weaker margin trajectory, and QBSS acquisition. We maintain ADD with a TP of Rs220/share at 20x Mar-26E EPS.

Firstsource Solutions: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Revenue	59,212	60,223	63,363	71,916	81,083
EBITDA	9,599	8,265	9,565	11,294	13,332
Adj. PAT	5,374	5,137	5,148	6,103	7,705
Adj. EPS (Rs)	7.7	7.4	7.4	8.8	11.1
EBITDA margin (%)	16.2	13.7	15.1	15.7	16.4
EBITDA growth (%)	19.4	(13.9)	15.7	18.1	18.0
Adj. EPS growth (%)	48.4	(4.4)	0.2	18.5	26.3
RoE (%)	18.4	16.1	14.6	15.7	17.8
RoIC (%)	16.8	12.1	13.7	14.9	17.4
P/E (x)	27.0	28.2	28.2	23.8	18.8
EV/EBITDA (x)	15.9	18.1	15.8	13.3	10.8
P/B (x)	4.8	4.3	3.9	3.6	3.2
FCFF yield (%)	4.4	5.1	3.9	5.4	6.3

Source: Company, Emkay Research

Results Summary

Revenue grew 4.7% QoQ (4.2% CC) to USD201mn, slightly higher than our estimate of USD199.5mn. Growth was broad based across all verticals — BFS (1.7% QoQ CC), Healthcare (3%), CMT (8%), and Diverse industries (7%). From geographies perspective, both US and UK grew 4% QoQ in CC. EBITM expanded ~30bps QoQ to 11%, in line with our estimates. Margin expansion was aided by normalization of the salary hikes undertaken in Q3. CMT and Healthcare margins contracted by 110bps and 190bps QoQ, respectively, while BFS margin expanded 200bps QoQ. Despite the offshore shift, top clients grew 13.8% QoQ on the back of additional business win. FSOL added 9 new logos in the quarter (6 in BFS, 2 in Healthcare, and 1 in CMT), with a total of 41 logos during FY24. It added 1,993 employees in Q4 (up 7.7% QoQ). **What we liked:** Broad-based growth in Q4, highest ACV win, steady FY25 guidance. **What we did not like:** Net debt remains largely unchanged at the end of FY24 at Rs6.04bn vs Rs6.16bn YoY.

Earnings Call KTAs

i) While the revenues were largely flat in H1, the company has seen growth acceleration in H2FY24. It has accelerated its participation in the cost optimization, revenue generation, and technology & process transformation agendas of clients. ii) Company added 9 new logos in Q4 and Management highlighted that the new logos are coming at deal sizes over 60% higher than last year. iii) BFSI, up 1.7% CC QoQ, was impacted by elevated interest rates, but clients continue to focus on cost optimization to drive efficiency in operations. iv) It also witnessed increased volumes in collection services with card issuers, credit card spending reaching record highs, and delinquencies also on the rise. v) A large transformational deal from one of its longstanding clients (announced in Q3) is well on track for ramp up. vi) Healthcare grew 3% CC QoQ in Q2. It announced 2 large deals in Q3, which have ramped-up well. While there was a minor impact in provider business due to a sudden drop in transactions in Q4, it was more than offset by increased volume on the payer side. vii) FSOL acquired QBSS for a cash consideration of USD39.2mn (EV/Sales: 2.65x). QBSS, headquartered in Chennai, provides RCM services for healthcare service providers and its intermediaries in the USA. The market for RCM solutions is estimated at USD25bn and is growing at double digits per year. viii) Despite the offshore shift in top clients, CMT grew 8% CC QoQ, aided by additional business and strong growth outside top clients. ix) Diverse vertical grew 7% CC QoQ, benefitted by strong demand in Energy & Utilities. x) In the US, the company expects growth to be driven by healthcare, CMT, and BFS, given the strength of FY24 exit pipeline.

Target Price – 12M	Mar-25
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	5.8
CMP (03-May-24) (Rs)	208.0

Stock Data	Ticker
52-week High (Rs)	229
52-week Low (Rs)	112
Shares outstanding (mn)	697.0
Market-cap (Rs bn)	145
Market-cap (USD mn)	1,738
Net-debt, FY25E (Rs mn)	4,730
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	532.3
ADTV-3M (USD mn)	6.4
Free float (%)	44.0
Nifty-50	22,476
INR/USD	83.4
Shareholding, Mar-24	
Promoters (%)	53.7
FPIs/MFs (%)	9.6/19.3

Price Performance

(%)	1M	3M	12M
Absolute	2.9	4.3	76.3
Rel. to Nifty	2.8	1.4	41.9

1-Year share price trend (Rs)



Dipesh Mehta

dipeshkumar.mehta@emkayglobal.com
+91 22 6612 1253

Ayush Bansal

ayush.bansal@emkayglobal.com
+91 22 6612 1344

Pulkit Chawla

pulkit.chawla@emkayglobal.com
+91 22 6642 4258

Exhibit 1: Quarterly snapshot

(Rs mn)	Q4FY24	Q3FY24	QoQ (%)	Q4FY23	YoY (%)
Revenues (USD mn)	201.0	192.0	4.7	190.0	5.8
Net sales	16,705	15,966	4.6	15,568	7.3
Total Income	16,705	15,966		15,568	
Operating expenses	14,201	13,595	4.5	13,127	8.2
EBITDA	2,504	2,371	5.6	2,441	2.6
Margins (%)	15.0	14.9	10	15.7	(70)
Depreciation	673	663		642	
EBIT	1,831	1,709	7.2	1,799	1.8
Margins (%)	11.0	10.7	30	11.6	(60)
Interest Paid	312	254		207	
Other income	75	154		127	
Non-recurring items	0	0		0	
Pre-tax profit	1,594	1,608	-0.9	1,719	-7.3
Tax provided	258	321		306	
Profit after tax	1,336	1,287		1,413	
Minority	0	0		0	
Emkay Net profit	1,336	1,287	3.8	1,413	-5.5
EPS (Rs)	1.9	1.8	3.8	2.0	(5.5)

Source: Company, Emkay Research

Exhibit 2: Actuals vs estimates


(Rs mn)	Actual	Estimate		Variation		Comments
		Emkay	Consensus	Emkay	Consensus	
Revenues (in USD mn)	201	200	199	0.7%	1.1%	Revenue was in line with our estimates
Sales	16,705	16,603	16,505	0.6%	1.2%	
EBIT	1,831	1,839	1,844	-0.4%	-0.7%	
EBIT, margin (%)	11.0%	11.1%	11.2%	-10 bps	-20 bps	Margins came in line with our expectations
PAT	1,336	1,342	1,345	-0.4%	-0.7%	In-line profits due to in-line operating performance

Source: Company, Bloomberg, Emkay Research

Exhibit 3: Changes in estimates

(Rs mn)	FY25E			FY26E		
	Old	New	Change	Old	New	Change
Revenues (USD mn)	847	857	1.2%	940	951	1.2%
USD revenues, YoY growth (%)	11.0%	12.0%		11.0%	11.0%	
Revenues	71,200	71,916	1.0%	80,261	81,083	1.0%
Revenues, YoY growth (%)	12.5%	13.5%		12.7%	12.7%	
EBIT	8,470	8,244	-2.7%	10,049	9,913	-1.4%
EBIT margin (%)	11.9%	11.5%		12.5%	12.2%	
PAT	6,358	6,103	-4.0%	7,858	7,705	-1.9%
EPS (Rs/share)	9.1	8.8	-4.0%	11.3	11.1	-1.9%

Source: Company, Emkay Research

Exhibit 4: FSOL – One-year forward P/E

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 06/27/2024 12:04 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Firstsource Solutions: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Revenue	59,212	60,223	63,363	71,916	81,083
Revenue growth (%)	16.6	1.7	5.2	13.5	12.7
EBITDA	9,599	8,265	9,565	11,294	13,332
EBITDA growth (%)	19.4	(13.9)	15.7	18.1	18.0
Depreciation & Amortization	2,494	2,632	2,602	3,049	3,419
EBIT	7,105	5,633	6,963	8,244	9,913
EBIT growth (%)	18.8	(20.7)	23.6	18.4	20.2
Other operating income	0	0	0	0	0
Other income	6	1,309	415	119	185
Financial expense	639	790	1,081	921	701
PBT	6,471	6,152	6,298	7,442	9,396
Extraordinary items	0	0	0	0	0
Taxes	1,106	1,015	1,150	1,340	1,691
Minority interest	8	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	5,374	5,137	5,148	6,103	7,705
PAT growth (%)	48.6	(4.4)	0.2	18.5	26.3
Adjusted PAT	5,374	5,137	5,148	6,103	7,705
Diluted EPS (Rs)	7.7	7.4	7.4	8.8	11.1
Diluted EPS growth (%)	48.4	(4.4)	0.2	18.5	26.3
DPS (Rs)	3.5	3.5	3.5	3.5	3.5
Dividend payout (%)	45.4	47.5	47.4	40.0	31.7
EBITDA margin (%)	16.2	13.7	15.1	15.7	16.4
EBIT margin (%)	12.0	9.4	11.0	11.5	12.2
Effective tax rate (%)	17.1	16.5	18.3	18.0	18.0
NOPLAT (pre-IndAS)	5,891	4,704	5,692	6,760	8,128
Shares outstanding (mn)	697.0	697.0	697.0	697.0	697.0

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
PBT	6,471	6,152	6,298	7,442	9,396
Others (non-cash items)	3,394	1,689	3,273	2,930	3,234
Taxes paid	(945)	(656)	(718)	(1,340)	(1,691)
Change in NWC	(1,884)	765	(2,404)	685	(472)
Operating cash flow	7,036	7,950	6,448	9,718	10,467
Capital expenditure	(729)	(514)	(850)	(1,899)	(1,290)
Acquisition of business	(5,067)	0	0	(1,600)	0
Interest & dividend income	5	10	10	119	185
Investing cash flow	(5,933)	134	(547)	(4,079)	(2,605)
Equity raised/(repaid)	37	0	0	0	0
Debt raised/(repaid)	3,905	(2,351)	(291)	(1,748)	(3,980)
Payment of lease liabilities	(1,170)	(1,495)	(1,993)	(1,500)	(1,500)
Interest paid	(580)	(787)	(1,011)	0	0
Dividend paid (incl tax)	(2,384)	(2,384)	(2,406)	(2,439)	(2,439)
Others	(500)	(140)	59	0	0
Financing cash flow	(1,580)	(7,434)	(5,642)	(5,688)	(7,919)
Net chg in Cash	(477)	650	259	(50)	(58)
OCF	7,036	7,950	6,448	9,718	10,467
Adj. OCF (w/o NWC chg.)	8,920	7,185	8,852	9,033	10,939
FCFF	6,307	7,436	5,597	7,819	9,177
FCFE	5,672	6,657	4,527	7,017	8,660
OCF/EBITDA (%)	73.3	96.2	67.4	86.0	78.5
FCFE/PAT (%)	105.5	129.6	87.9	115.0	112.4
FCFF/NOPLAT (%)	107.1	158.1	98.3	115.7	112.9

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Share capital	6,970	6,970	6,970	6,970	6,970
Reserves & Surplus	23,360	26,699	30,034	33,697	38,963
Net worth	30,329	33,668	37,004	40,667	45,933
Minority interests	4	4	4	4	4
Deferred tax liability (net)	959	1,196	1,470	1,470	1,470
Total debt	9,683	6,665	8,123	7,680	3,700
Total liabilities & equity	40,975	41,533	46,601	49,821	51,107
Net tangible fixed assets	2,285	1,739	1,628	1,625	1,577
Net intangible assets	1,186	1,015	650	1,063	788
Net ROU assets	6,758	4,958	6,366	6,448	6,141
Capital WIP	29	34	171	30	30
Goodwill	27,208	29,450	29,885	31,485	31,485
Investments [JV/Associates]	0	0	0	0	0
Cash & equivalents	2,198	2,267	2,300	2,950	4,392
Current assets (ex-cash)	17,423	17,180	19,829	20,421	21,975
Current Liab. & Prov.	16,112	15,111	14,229	14,200	15,281
NWC (ex-cash)	1,311	2,069	5,600	6,221	6,693
Total assets	40,975	41,533	46,601	49,821	51,107
Net debt	7,485	4,398	5,823	4,730	(692)
Capital employed	40,975	41,533	46,601	49,821	51,107
Invested capital	38,747	39,232	44,130	46,841	46,684
BVPS (Rs)	43.5	48.3	53.1	58.3	65.9
Net Debt/Equity (x)	0.2	0.1	0.2	0.1	0.0
Net Debt/EBITDA (x)	0.8	0.5	0.6	0.4	(0.1)
Interest coverage (x)	0.1	0.1	0.1	0.1	0.1
RoCE (%)	19.0	16.8	16.7	17.3	20.0

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY22	FY23	FY24	FY25E	FY26E
P/E (x)	27.0	28.2	28.2	23.8	18.8
P/CE(x)	18.4	18.7	18.7	15.8	13.0
P/B (x)	4.8	4.3	3.9	3.6	3.2
EV/Sales (x)	2.6	2.5	2.4	2.1	1.8
EV/EBITDA (x)	15.9	18.1	15.8	13.3	10.8
EV/EBIT(x)	21.5	26.5	21.7	18.2	14.6
EV/IC (x)	3.9	3.8	3.4	3.2	3.1
FCFF yield (%)	4.4	5.1	3.9	5.4	6.3
FCFE yield (%)	3.9	4.6	3.1	4.8	6.0
Dividend yield (%)	1.7	1.7	1.7	1.7	1.7
DuPont-RoE split					
Net profit margin (%)	9.1	8.5	8.1	8.5	9.5
Total asset turnover (x)	1.6	1.5	1.4	1.5	1.6
Assets/Equity (x)	1.3	1.3	1.2	1.2	1.2
RoE (%)	18.4	16.1	14.6	15.7	17.8
DuPont-RoIC					
NOPLAT margin (%)	9.9	7.8	9.0	9.4	10.0
IC turnover (x)	1.7	1.5	1.5	1.6	1.7
RoIC (%)	16.8	12.1	13.7	14.9	17.4
Operating metrics					
Core NWC days	8.1	12.5	32.3	31.6	30.1
Total NWC days	8.1	12.5	32.3	31.6	30.1
Fixed asset turnover	1.4	1.3	1.3	1.3	1.4
Opex-to-revenue (%)	83.8	86.3	84.9	84.3	83.6

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 06/27/2024 12:04 PM


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
31-Mar-24	198	220	Add	Dipeshkumar Mehta
01-Mar-24	205	220	Add	Dipeshkumar Mehta
08-Feb-24	217	220	Add	Dipeshkumar Mehta
31-Dec-23	185	190	Add	Dipeshkumar Mehta
30-Nov-23	178	190	Add	Dipeshkumar Mehta
16-Nov-23	166	190	Buy	Dipeshkumar Mehta
08-Nov-23	160	190	Buy	Dipeshkumar Mehta
02-Oct-23	168	190	Buy	Dipeshkumar Mehta
04-Aug-23	149	160	Buy	Dipeshkumar Mehta
02-Jul-23	127	135	Buy	Dipeshkumar Mehta
05-May-23	113	130	Buy	Dipeshkumar Mehta
01-Apr-23	106	130	Buy	Dipeshkumar Mehta
03-Feb-23	116	130	Buy	Dipeshkumar Mehta
02-Jan-23	103	125	Buy	Dipeshkumar Mehta
03-Nov-22	104	125	Buy	Dipeshkumar Mehta
04-Oct-22	105	130	Buy	Dipeshkumar Mehta
04-Aug-22	105	130	Buy	Dipeshkumar Mehta
23-Jun-22	100	140	Buy	Dipeshkumar Mehta
06-May-22	112	170	Buy	Dipeshkumar Mehta
01-Apr-22	128	180	Buy	Dipeshkumar Mehta
22-Feb-22	122	180	Buy	Dipeshkumar Mehta
04-Feb-22	153	210	Buy	Dipeshkumar Mehta
01-Jan-22	183	230	Buy	Dipeshkumar Mehta
30-Dec-21	183	230	Buy	Dipeshkumar Mehta
30-Nov-21	170	230	Buy	Dipeshkumar Mehta
23-Nov-21	170	220	Buy	Dipeshkumar Mehta
10-Nov-21	180	220	Buy	Dipeshkumar Mehta
02-Oct-21	195	220	Hold	Dipeshkumar Mehta
27-Aug-21	182	220	Hold	Dipeshkumar Mehta
30-Jul-21	195	210	Hold	Dipeshkumar Mehta
02-Jul-21	189	210	Hold	Dipeshkumar Mehta
12-May-21	128	145	Buy	Dipeshkumar Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of May 3, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of May 3, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 3, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.